Search Result

Pathways Recommended:	PI3K/Akt/mTOR
Isoforms Recommended:	Akt3

Results for "

AKT3

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (32) AMPK (2) Apoptosis (5) Autophagy (5) Organoid (4) Parasite (2) PKA (4) PKC (4) PROTAC Linkers (1) PROTACs (4) Ribosomal S6 Kinase (RSK) (4) ROCK (4) Ser/Thr Protease (1) SGK (2) Small Interfering RNA (siRNA) (3)
By Research Areas:	Cancer (34) Infection (2) Metabolic Disease (1)
Click Chemistry:	PROTAC Synthesis (1) Alkynes (1)

Inhibitors & Agonists

Recombinant Proteins

Antibodies

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-151606

Akt3 degrader 1	Akt	Cancer
Akt3 degrader 1 (compound 12l) is a selective *Akt3* degrader that overcomes Osimertinib (HY-15772)-induced resistance in H1975OR NSCLC cells. Akt3 degrader 1 also has anti-proliferative activity and significantly inhibits tumour growth in mice. Akt3 degrader 1 can be used in the study of drug-resistant non-small cell lung cancer .

HY-RS00549

AKT3 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
AKT3 Human Pre-designed siRNA Set A contains three designed siRNAs for AKT3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

AKT3 Human Pre-designed siRNA Set A AKT3 Human Pre-designed siRNA Set A

HY-RS00550

Akt3 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Akt3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Akt3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Akt3 Mouse Pre-designed siRNA Set A Akt3 Mouse Pre-designed siRNA Set A

HY-RS00551

Akt3 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Akt3 Rat Pre-designed siRNA Set A contains three designed siRNAs for Akt3 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Akt3 Rat Pre-designed siRNA Set A Akt3 Rat Pre-designed siRNA Set A

HY-143611

AKT-IN-8

Akt Cancer

AKT-IN-8 is a potent AKT inhibitor with IC₅₀s of 4.46, 2.44, and 9.47 nM for AKT1, AKT2, and AKT3, respectively .

AKT-IN-8	Akt	Cancer
AKT-IN-8 is a potent *AKT* inhibitor with IC₅₀s of 4.46, 2.44, and 9.47 nM for AKT1, AKT2, and AKT3, respectively .

HY-153640

AKT-IN-14	Akt	Cancer
AKT-IN-14 (Example 2) is a potent AKTinhibitor with the IC₅₀ values of <0.01 nM, 1.06 nM and 0.66 nM for AKT1, AKT2, AKT3, respectively. AKT-IN-14 can be used in cancer research .

HY-153640A

AKT-IN-14 free base	Akt	Cancer
AKT-IN-14 (Example 2) free baseis a potent AKTinhibitor with the IC₅₀ values of <0.01 nM, 1.06 nM and 0.66 nM for AKT1, AKT2, AKT3, respectively. AKT-IN-14 free basecan be used in cancer research .

HY-145281

MS98	PROTACs Akt	Cancer
MS98 is a potent and selective PROTAC AKT degrader. MS98 depletes cellular total *AKT* (T-AKT) with the DC₅₀ value of 78 nM. MS98 binds to AKT1, AKT2, and AKT3 with K_ds of 4 nM, 140 nM, and 8.1 nM, respectively .

HY-145282

MS170	PROTACs Akt	Cancer
MS170 is a potent and selective PROTAC AKT degrader. MS170 depletes cellular total *AKT* (T-AKT) with the DC₅₀ value of 32 nM. MS170 binds to AKT1, AKT2, and AKT3 with K_ds of 1.3 nM, 77 nM, and 6.5 nM, respectively .

HY-15965

Uprosertib 15+ Cited Publications GSK2141795	Akt	Cancer
Uprosertib (GSK2141795) is a potent and selective *pan-Akt* inhibitor with IC₅₀ values of 180/328/38 nM for Akt1/Akt2/Akt3, respectively.

HY-15965A

Uprosertib hydrochloride GSK2141795 (hydrochloride)	Akt	Cancer
Uprosertib hydrochloride (GSK2141795 hydrochloride) is a potent and selective *pan-Akt* inhibitor with IC₅₀ values of 180/328/38 nM for Akt1/Akt2/Akt3, respectively.

HY-10425

A-443654

5+ Cited Publications

Akt Cancer

A-443654 is a pan-Akt inhibitor and has equal potency against Akt1, Akt2, or Akt3 within cells (K_i=160 pM) .

A-443654 5+ Cited Publications	Akt	Cancer
A-443654 is a *pan-Akt* inhibitor and has equal potency against *Akt1, Akt2, or Akt3* within cells (K_i=160 pM) .

HY-15431

Capivasertib 45+ Cited Publications AZD5363	Akt Autophagy	Cancer
Capivasertib (AZD5363) is an orally active and potent *pan-AKT* kinase inhibitor with IC₅₀ of 3, 7 and 7 nM for *Akt1,Akt2* and *Akt3*, respectively.

HY-15186A

Ipatasertib dihydrochloride 30+ Cited Publications GDC-0068 dihydrochloride; RG-7440 dihydrochloride	Organoid Akt	Cancer
Ipatasertib dihydrochloride (GDC-0068 dihydrochloride) is a highly selective and ATP-competitive *pan-Akt* inhibitor with IC₅₀s of 5, 18 and 8 nM for *Akt1, Akt2* and *Akt3*, respectively.

HY-15727

Afuresertib 10+ Cited Publications GSK2110183; LAE002	Akt PKC ROCK	Cancer
Afuresertib (GSK2110183) is an orally bioavailable, selective, ATP-competitive and potent pan-Akt kinase inhibitor with K_is of 0.08/2/2.6 nM for Akt1/Akt2/Akt3, respectively .

HY-15727A

Afuresertib hydrochloride 10+ Cited Publications GSK2110183 hydrochloride; LAE002 hydrochloride	Akt PKC ROCK	Cancer
Afuresertib hydrochloride (GSK 2110183 hydrochloride) is an orally bioavailable, selective, ATP-competitive and potent pan-Akt kinase inhibitor with K_is of 0.08/2/2.6 nM for Akt1/Akt2/Akt3 respectively .

HY-19719

Miransertib 5+ Cited Publications ARQ-092	Akt Parasite	Infection Cancer
Miransertib (ARQ-092) is a potent, orally active, selective and allosteric *Akt* inhibitor with IC₅₀s of 2.7 nM, 14 nM and 8.1 nM for *Akt1, Akt2, Akt3, respectively. Miransertib is also a potent the AKT1-E17K mutant protein inhibitor and has the potential for PI3K/AKT-driven tumors and Proteus syndrome research . Miransertib is effective against Leishmania* .

HY-19719A

Miransertib hydrochloride 5+ Cited Publications ARQ-092 hydrochloride	Akt Parasite	Infection Cancer
Miransertib hydrochloride (ARQ-092 hydrochloride) is a potent, orally active, selective and allosteric *Akt* inhibitor with IC₅₀s of 2.7 nM, 14 nM and 8.1 nM for *Akt1, Akt2, Akt3, respectively. Miransertib hydrochloride is also a potent the AKT1-E17K mutant protein inhibitor and has the potential for PI3K/AKT-driven tumors and Proteus syndrome research . Miransertib hydrochloride is effective against Leishmania* .

HY-133120

INY-03-041	PROTACs Akt	Cancer
INY-03-041 is a potent, highly selective and PROTAC-based pan-AKT degrader consisting of the ATP-competitive *AKT* inhibitor Ipatasertib (HY-15186) conjugated to Lenalidomide (HY-A0003, Cereblon ligand). INY-03-041 inhibits *AKT1, AKT2* and *AKT3* with IC₅₀s of 2.0, 6.8 and 3.5 nM, respectively .

HY-19982

AKT-IN-6

AKT-IN-6 (Example 13) is a potent Akt inhibitor. AKT-IN-6 inhibits Akt1, Akt2 and Akt3 with IC₅₀s < 500nM, respectively. (patent WO2013056015A1).

AKT-IN-6
AKT-IN-6 (Example 13) is a potent Akt inhibitor. AKT-IN-6 inhibits Akt1, Akt2 and Akt3 with IC₅₀s < 500nM, respectively. (patent WO2013056015A1).

HY-12059

AT7867 4 Publications Verification	Akt PKA Ribosomal S6 Kinase (RSK)	Cancer
AT7867 is a potent ATP-competitive inhibitor of *Akt1/Akt2/Akt3* and p70S6K/PKA with IC₅₀s of 32 nM/17 nM/47 nM and 85 nM/20 nM, respectively.

HY-12059A

AT7867 dihydrochloride 4 Publications Verification	Akt PKA Ribosomal S6 Kinase (RSK)	Cancer
AT7867 dihydrochloride is a potent ATP-competitive inhibitor of *Akt1/Akt2/Akt3* and p70S6K/PKA with IC₅₀s of 32 nM/17 nM/47 nM and 85 nM/20 nM, respectively.

HY-10355

AKT inhibitor VIII 35+ Cited Publications AKTi-1/2	Akt Apoptosis	Metabolic Disease Cancer
AKT inhibitor VIII (AKTi-1/2) is a cell-permeable quinoxaline compound that has been shown to potently, selectively, allosterically, and reversibly inhibit *Akt1, Akt2, and Akt3* activity with IC₅₀s of 58 nM, 210 nM, and 2119 nM, respectively.

HY-132302

Hu7691	Akt PKA PKC ROCK Ribosomal S6 Kinase (RSK) SGK	Cancer
Hu7691 is an orally active, selective *Akt* inhibitor with IC₅₀s of 4.0 nM, 97.5 nM, 28 nM for Akt1, Akt2 and Akt3, respectively. Hu7691 inhibits tumor growth and enables decrease of cutaneous toxicity in mice .

HY-147937

AKT-IN-13	Akt	Cancer
AKT-IN-13 (compound 4b) is a potent *Akt* inhibitor with IC₅₀s of 1.6 nM, 2.4 nM and 0.3 nM for Akt1, Akt2 and Akt3, respectively. AKT-IN-13 can be used for researching anticancer .

HY-10358

MK-2206 dihydrochloride Maximum Cited Publications 286 Publications Verification MK-2206 (2HCl)	Organoid Akt Autophagy Apoptosis	Cancer
MK-2206 dihydrochloride (MK-2206 (2HCl)) is an orally active, BBB-penetrated allosteric *AKT* inhibitor with IC₅₀s of 5 nM, 12 nM, and 65 nM for *AKT1, AKT2, and AKT3, respectively. MK-2206 dihydrochloride induces autophagy* .

HY-132302A

Hu7691 free base	Akt PKA PKC ROCK Ribosomal S6 Kinase (RSK) SGK	Cancer
Hu7691 free base is an orally active, selective *Akt* inhibitor with IC₅₀s of 4.0 nM, 97.5 nM, 28 nM for Akt1, Akt2 and Akt3, respectively. Hu7691 free base inhibits tumor growth and enables decrease of cutaneous toxicity in mice .

HY-100501

M2698 MSC2363318A
M2698 (MSC2363318A) is an orally active, ATP competitive, selective p70S6K and *Akt* dual-inhibitor with IC₅₀s of 1 nM for p70S6K, Akt1 and Akt3. M2698 can cross the blood-brain barrier and has anti-cancer activity .

HY-151504

ALM301 1 Publications Verification	Akt	Cancer
ALM301 is an orally active highly specific *AKT* inhibitor with IC₅₀ values of 0.13 µM, 0.09 µM and 2.75 µM for AKT1, AKT2 and AKT3, respectively. ALM301 inhibits AKT phosphorylation and modulates downstream signalling in vitro. ALM301 can inhibit cancer cell proliferation and tumor growth .

HY-10249

GSK-690693 25+ Cited Publications	Akt AMPK Autophagy	Cancer
GSK-690693 is an ATP-competitive *pan-Akt* inhibitor with IC₅₀s of 2 nM, 13 nM, 9 nM for *Akt1, Akt2* and *Akt3, respectively. GSK-690693 is also an AMPK* inhibitor, affects Unc-51-like autophagy activating kinase 1 (ULK1) activity and robustly inhibits STING-dependent IRF3 activation ^[3].

HY-108232

MK-2206	Organoid Akt Autophagy Apoptosis	Cancer
MK-2206 is an orally active, highly potent and selective allosteric *Akt* inhibitor, with IC₅₀s of 8, 12, and 65 nM for Akt1, Akt2, and Akt3, respectively. Many breast cancer cell lines, and PIK3CA-mutant and cell lines with PTEN loss are sensitive to MK-2206. MK-2206 has anticancer activities .

HY-133120A

INY-03-041 trihydrochloride	PROTACs Akt	Cancer
INY-03-041 trihydrochloride is a potent, highly selective and PROTAC-based pan-AKT degrader consisting of the ATP-competitive *AKT* inhibitor Ipatasertib (HY-15186) conjugated to Lenalidomide (HY-A0003, Cereblon ligand). INY-03-041 trihydrochloride inhibits *AKT1, AKT2* and *AKT3* with IC₅₀s of 2.0, 6.8 and 3.5 nM, respectively .

HY-137458

Vevorisertib ARQ 751	Akt Ser/Thr Protease	Cancer
Vevorisertib (ARQ 751) is an orally active, potent and selective *pan-AKT* serine/threonine kinase inhibitor against *AKT1* (IC₅₀=0.55 nM), *AKT2* (IC₅₀=0.81 nM), and *AKT3* (IC₅₀=1.31 nM). Vevorisertib, as a single agent or in combination with other anti-cancer agents, can be used for the research of solid tumors with PIK3CA / AKT / PTEN mutations ^[3] .

HY-147935

NTQ1062	Akt	Cancer
NTQ1062 is a potent and orally active *Akt* inhibitor with IC₅₀s of 0.4 nM, 6.3 nM and 0.1 nM for Akt1, Akt2 and Akt3, respectively. NTQ1062 induces cell apoptosis and arrests the cell cycle at G0/G1 phase. NTQ1062 exhibits antiproliferation activity against various cancer cells. NTQ1062 exhibits potent antitumor efficacy in LNCap xenograft mouse model .

HY-10357

MK-2206 free base	Organoid Akt Autophagy Apoptosis	Cancer
MK-2206 free base is an orally active, highly potent and selective allosteric *Akt* inhibitor, with IC₅₀s of 8, 12, and 65 nM for Akt1, Akt2, and Akt3, respectively. Many breast cancer cell lines, and PIK3CA-mutant and cell lines with PTEN loss are sensitive to MK-2206 free base. MK-2206 free base has anticancer activities .

HY-137458A

Vevorisertib trihydrochloride ARQ 751 trihydrochloride	Akt	Cancer
Vevorisertib (ARQ 751) trihydrochloride is a selective, allosteric, pan-AKT and AKT1-E17K mutant inhibitors. Vevorisertib trihydrochloride potently inhibit phosphorylation of AKT. Vevorisertib trihydrochloride has Kd values of 1.2 nM and 8.6 nM for AKT1 and AKT1-E17K, respectively. Vevorisertib trihydrochloride has IC₅₀ values of 0.55, 0.81, and 1.3 nM for AKT1, AKT2, and AKT3, respectively. Vevorisertib trihydrochloride can be used for the research of cancer .

HY-126257

AKT-IN-3	Akt Apoptosis	Cancer
AKT-IN-3 (compound E22) is a potent, orally active low hERG blocking *Akt* inhibitor, with 1.4 nM, 1.2 nM and 1.7 nM for Akt1, Akt2 and Akt3, respectively. AKT-IN-3 (compound E22) also exhibits good inhibitory activity against other AGC family kinases, such as PKA, PKC, ROCK1, RSK1, P70S6K, and SGK. AKT-IN-3 (compound E22) induces apoptosis and inhibits metastasis of cancer cells .

HY-130985

9-Decyn-1-ol	PROTAC Linkers	Cancer
9-Decyn-1-ol is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs. 9-Decyn-1-ol can be used to conjugate GDC-0068 with Lenalidomide to generate INY-03-041. INY-03-041 is a potent, highly selective and PROTAC-based pan-Akt degrader. INY-03-041 inhibits Akt1, Akt2 and Akt3 with IC₅₀s of 2.0 nM, 6.8 nM and 3.5 nM, respectively . 9-Decyn-1-ol is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-112083

BAY-3827 2 Publications Verification	AMPK	Cancer
BAY-3827 is a potent and selective AMPK inhibitor with IC₅₀ values of 1.4 nM at low (10 µM ATP concentration) and 15 nM at high (2 mM ATP concentration). BAY-3827 shows over 500-fold selectivity for most of the 331 kinases. BAY-3827 prevents phosphorylation of acetyl-CoA carboxylase 1 and shows strongest anti-proliferative activity in androgen-dependent prostate cancer cell lines .

Recombinant Proteins Recommended:

AKT Serine/Threonine Kinase 3 (AKT3)

Species:	Human (2) Mouse (2)
Tag:	His (1) Tag Free (1) GST (3)
Source:	Sf9 insect cells (4)

Cat. No.	Compare	Product Name	Species	Source

HY-P75519

	AKT3 Protein, Human (sf9, GST) RAC-gamma serine/threonine-protein kinase; Protein kinase AKT-3; PKB gamma; AKT3	Human	Sf9 insect cells
	The AKT3 protein, like AKT1 and AKT2, is an important member of the AKT kinase family and plays a central role in a variety of cellular processes, including metabolism, proliferation, survival, growth, and angiogenesis. AKT3 has more than 100 reported targets and coordinates complex signaling pathways that control glucose uptake, regulate glycogen storage, and influence neurogenesis. AKT3 Protein, Human (sf9, GST) is the recombinant human-derived AKT3 protein, expressed by Sf9 insect cells , with N-GST labeled tag. The total length of AKT3 Protein, Human (sf9, GST) is 479 a.a., with molecular weight of ~81 kDa.

HY-P72817

	AKT3 Protein, Mouse (sf9) RAC-gamma serine/threonine-protein kinase; Protein kinase AKT-3; PKB gamma; AKT3	Mouse	Sf9 insect cells
	AKT3 Protein, part of the AKT kinase family, regulates diverse cellular processes, including metabolism, proliferation, and survival. Its least studied isoform, AKT3, is vital for brain development and essential for malignant glioma cell viability. AKT3 also plays a role in coordinating mitochondrial biogenesis with energy demands and modulating MMP13 expression via IL13. RNA interference-induced down-regulation leads to decreased phosphorylated BAD and triggers caspase-dependent apoptosis. AKT3 Protein, Mouse (sf9) is the recombinant mouse-derived AKT3 protein, expressed by Sf9 insect cells , with tag free. The total length of AKT3 Protein, Mouse (sf9) is 374 a.a., with molecular weight of ~46 kDa.

HY-P75518

	AKT3 Protein, Mouse (sf9, His-GST) RAC-gamma serine/threonine-protein kinase; Protein kinase AKT-3; PKB gamma; AKT3	Mouse	Sf9 insect cells
	The AKT3 protein is part of the AKT kinase family and regulates a variety of cellular processes, including metabolism, proliferation, and survival. Its least-studied isoform, AKT3, is critical for brain development and is critical for the viability of malignant glioma cells. AKT3 Protein, Mouse (sf9, His-GST) is the recombinant mouse-derived AKT3 protein, expressed by Sf9 insect cells , with N-His, N-GST labeled tag. The total length of AKT3 Protein, Mouse (sf9, His-GST) is 374 a.a., with molecular weight of ~65 kDa.

HY-P702633

	AKT3 Protein, Human (Active, sf9, GST) AKT3; AKT serine/threonine kinase 3; MPPH; PKBG; MPPH2; PRKBG; STK-2; PKB-GAMMA; RAC-gamma; RAC-PK-gamma; RAC-gamma serine/threonine-protein kinase; PKB gamma; RAC-gamma serine/threonine protein kinase; v-AKT murine thymoma viral oncogene homolog 3 (protein kinase B, gamma); EC 2.7.11.1	Human	Sf9 insect cells


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Application	Reactivity

HY-P80535

AKT1/AKT2/AKT3 Antibody (YA635) AKT1,AKT2,AKT3	WB, IHC-F, IHC-P, ICC/IF, IP	Human, Mouse, Rat, Hamster
AKT Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 56 kDa, targeting to AKT. It can be used for WB,IHC-F,IHC-P,ICC/IF,IP assays with tag free, in the background of Human, Mouse, Rat, Hamster.

Cat. No.	Product Name		Classification

HY-130985

9-Decyn-1-ol		Alkynes PROTAC Synthesis
9-Decyn-1-ol is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs. 9-Decyn-1-ol can be used to conjugate GDC-0068 with Lenalidomide to generate INY-03-041. INY-03-041 is a potent, highly selective and PROTAC-based pan-Akt degrader. INY-03-041 inhibits Akt1, Akt2 and Akt3 with IC₅₀s of 2.0 nM, 6.8 nM and 3.5 nM, respectively . 9-Decyn-1-ol is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: